org): a yearly weeklong series of events, activities = $1. >;89.*7 28=.,1 '..4 @@@ +28=.,1@..4 org): a yearly in weeklong events, activities and initiatives Memberseries Statesofexplaining and cel8;0 * B.*;5B @..45870 <.;2.< 8/ .?.7=< *,=2?2=2.< and initiatives in Member States explaining and celebrating biotech across Europe. *7- 272=2*=2?.< 27 .6+.; #=*=.< .A95*27270 *7- ,.5 ebrating biotech across Europe. Âˇ The EuropaBio BeneďŹ ts Event features short pres350 million patients Seeking to relieve Âˇ .+;*=270 +28=.,1 *,;8<< >;89. The EuropaBio BeneďŹ ts Event features short presentations by CEOs of leading biotech companies on 350 million patients already benefiting Seeking to relieve Europabio 20 to 30 million = $1. >;89* 28 .7. =< ?.7= /.*=>;.< <18;= 9;.< entations by CEOs of leading biotech companies 350 patients already benefiting from million treatment Seeking to relieve rareto disease patients 20 30 million concrete examples of where biotech has madeon a .7=*=287< +B < 8/ 5.*-270 +28=.,1 ,869*72.< 87 from treatment already benefiting rareto disease patients 20 30 million concrete examples of society, where biotech has made a positive contribution to as well as â€˜testimonifrom treatment rare disease patients ,87,;.=. .A*695.< 8/ @1.;. +28=.,1 1*< 6*-. * Targeted treatments positive to experiencing society, as well as â€˜testimonialsâ€™ fromcontribution end-users on biotech beneďŹ ts for many diseases Targeted treatments 98<2=2?. ,87=;2+>=287 =8 <8,2.=B *< @.55 *< D=.<=26872 50% alsâ€™ from end-users on experiencing biotech beneďŹ ts ďŹ rst-hand. for many diseases Targeted treatments Insulin, Factor VIII coagulant for haemophiliacs, 50% of all medicines *5<.;< 87 .A9.;2.7,270 +28=.,1 +.7. =< ďŹ rst-hand. antibodies for cancer, orphan medicinal products for many diseases Insulin, Factor VIII coagulant for haemophiliacs, Âˇ EuropaBioâ€™s Most Innovative European Biotech SME 50% will from of allcome medicines for rare diseases, vaccines, advanced therapies that antibodies for cancer, orphan medicinal products ;<= 1*7- Insulin, Factor VIII coagulant for haemophiliacs, Âˇ Award: EuropaBioâ€™s Most Innovative European Biotech SME biotech in from 2015 repair skin, bones and cartilage damagethat will of allcome medicines d[ Vaa bZY^X^cZh a yearly award recognizing European biotech for rareorgans, diseases, vaccines, advanced therapies antibodies for cancer, orphan medicinal products = >;89* 28E< 8<= 778?*=2?. >;89.*7 28=.,1 # biotech in 2015 repair organs, skin, bones and cartilage damage will come from XVbZ [gdb Award: a yearly award recognizing European biotech for rare diseases, vaccines, advanced therapies that SMEs that have developed innovative solutions to biotech in 2015 repair organs, skin, bones and cartilage damage W^diZX] ^c '%&* @*;- * B.*;5B *@*;- ;.,8072C270 >;89.*7 +28=.,1 SMEs that have developed innovative solutions in thesocietal three specific sectors (healthcare, agriculture, and to challenges. # < =1*= 1*?. -.?.589.- 2778?*=2?. <85>=287< =8 societal challenges. industry) well as aForum series of initiatives Âˇ The as European oncross-sectoral Industrial Biotechnology Âˇ <8,2.=*5 ,1*55.70.< The European Forum on Industrial Biotechnology such as: the and Biobased Economy (EFIB, www.eďŹ bforum. = $1. >;89.*7 8;>6 87 7-><=;2*5 28=.,178580B and the Economy (EFIB, www.eďŹ bforum. com): anBiobased event providing insight in the exciting and ÂˇÂˇ The European Biotech Week (www.biotechweek.org): *7- =1. 28+*<.- ,8786B @@@ . +/8;>6 AGRICULTURAL BIOTECH com): an event providing insight in the exciting and rapidly evolving industrial biotech landscape that has a yearly weeklong series of events, activities and iniAGRICULTURAL BIOTECH ,86 *7 .?.7= 9;8?2-270 27<201= 27 =1. .A,2=270 *7- rapidly evolving industrial biotech landscape that has AGRICULTURAL BIOTECH become a part of the process of building a stronger, tiatives in Member States explaining and celebrating ;*92-5B .?85?270 27-><=;2*5 +28=.,1 5*7-<,*9. =1*= 1*< become a part of the process of building a stronger, more sustainable European biobased economy. 18 million biotech across Europe. +.,86. * 9*;= 8/ =1. 9;8,.<< 8/ +>25-270 * <=;870.; Built-in protection farmers more sustainable European biobased economy. 18 million globally on Built-in protection against insects farmers 68;. <><=*27*+5. >;89.*7 +28+*<.- .,8786B 18 million globally on BEING PART OF THEBiotech SME Awards Âˇ Âˇ The Most Innovative European against insects Built-in protection farmers 175 million hectares BEING PART OF THEThree awards recogglobally on against insects hectares 175 million EUROPABIO STORY (www.biotechsmeawards.eu): Equivalent to Less fuel ! "$ $ EUROPABIO STORY 175 million hectares Our membership is composed of 60 mem7.8 million to nising European biotech SMEs from thecorporate three sectors Equivalent LessC0fuel and Reduced 2 %" ! #$ "( Our membership is composed of 60 corporate memless cars 7.8 million to Equivalent LessC0fuel and Reduced bers, 13 associate members and Bio regions, and soil erosion of biotechnology (healthcare, industry and agricul- 17 2 less cars >; 6.6+.;<129 2< ,8698<.- 8/ ,8;98;*=. 6.6 7.8 million bers, 13 associate members and Bio regions, and 17 and C02 Reduced soil erosion national associations, who in turn ture) thatbiotechnology have developed innovative solutions to represoless cars +.;< *<<8,2*=. 6.6+.;< *7- 28 ;.0287< *7- soil erosion national biotechnology associations, who in turn repreLess toxins 6% to 30% sent than 1800 small and medium sized biotech cietalmore challenges. 7*=287*5 +28=.,178580B *<<8,2*=287< @18 27 =>;7 ;.9;. Less in foodtoxins 6% to 30% more yield sent more than 1800 small and medium sized biotech companies in Europe. Members of EuropaBio are inLess in foodtoxins 6% to 30% more yield <.7= 68;. =1*7 <6*55 *7- 6.-2>6 <2C.- +28=.,1 companies in Europe. Members of EuropaBio are involved in research, development, testing, manufacturin food Âˇ Âˇ The European Forum on Industrial Biotechnology and more yield ,869*72.< 27 >;89. .6+.;< 8/ >;89* 28 *;. 27 volved in research, development, testing, manufacturing commercialisation of biotechnology products the and Biobased Economy (EFIB, www.efibforum.com): ?85?.- 27 ;.<.*;,1 -.?.5896.7= =.<=270 6*7>/*,=>; ing and commercialisation of biotechnology products and processes. Our corporate members have a wide an event providing insight in the exciting and rapidly 270 *7- ,866.;,2*52<*=287 8/ +28=.,178580B 9;8->,=< and processes. Our corporate members have a wide range of activities: human and animal health care, evolving industrial>; ,8;98;*=. 6.6+.;< 1*?. * @2-. biotech landscape that has be-di*7- 9;8,.<<.< range of activities: human and animal health care, diagnostics, bio-informatics, chemicals, crop protection, come a part of the process of building a stronger, ;*70. 8/ *,=2?2=2.< 1>6*7 *7- *726*5 1.*5=1 ,*;. -2 INDUSTRIAL BIOTECH agnostics, bio-informatics, chemicals, crop protection, agriculture, foodEuropean and environmental products and more sustainable bio-based economy. INDUSTRIAL BIOTECH *078<=2,< +28 27/8;6*=2,< ,1.62,*5< ,;89 9;8=.,=287 agriculture, food and environmental products and services. INDUSTRIAL BIOTECH *0;2,>5=>;. /88- *7- .7?2;876.7=*5 9;8->,=< *7- services. Spares 33 million tonnes Greener transport EuropaBio also welcomes associate members such as Spares 33 million tonnes <.;?2,.< Greener transport thanks to biofuels, of CO2 emissions. EuropaBio also welcomesďŹ nancial, associateasset members such as international commercial, management rubber tyres, Spares 33 million tonnes Being part of EuropaBio story Greener transport thanks to biofuels, emissions. of CO2Equivalent >;89* 28 *5<8 @.5,86.< *<<8,2*=. 6.6+.;< <>,1 *< to the energy use international commercial, ďŹ nancial, asset management bioplastic parts rubber to tyres, and other service-providing companies, regional biothanks biofuels, of CO2Equivalent ofemissions. 2.5 million per use year to homes the energy Members of EuropaBio are involved in research, devel27=.;7*=287*5 ,866.;,2*5 7*7,2*5 *<<.= 6*7*0.6.7= bioplastic parts and other service-providing companies,and regional biorubber tyres, of 2.5 million per use year technology development organisations scientiďŹ c Equivalent to homes the energy opment, testing, manufacturing and commercialisation bioplastic parts *7- 8=1.; <.;?2,. 9;8?2-270 ,869*72.< ;.0287*5 +28 of 2.5 million homes per year Materials technology development organisations and scientiďŹ c More effective detergents institutes. The products commonand denominator all our of =.,178580B -.?.5896.7= 8;0*72<*=287< *7- <,2.7=2 , biotechnology processes.among Our corpoMaterials More allow effective to save detergents up to 30% (including plastics) made institutes. The common denominatorat among all our members is the use of biotechnology any stage Materials More of effective detergents the electricity used on rate members have a wide range of activities: human of from renewable resources allow to save up to 30% (including plastics) made 27<=2=>=.< $1. ,86687 -.78627*=8; *6870 *55 8>; members is the use of biotechnology at any stage of 30Â°C laundry by washing at instead of fossil fuels of the to electricity used on research, development or manufacturing. from renewable resources allow save up to 30% (including plastics) made and animal healthcare, diagnostics, bio-informatics, 6.6+.;< 2< =1. ><. 8/ +28=.,178580B *= *7B <=*0. 8/ 30Â°C laundry by washing at on instead of fossil fuels research, development or manufacturing. of the electricity used from renewable resources We lead an innovative andagriculture, dynamic industry andenvimemchemicals, crop protection, food and laundry by washing at 30Â°C instead of fossil fuels ;.<.*;,1 -.?.5896.7= 8; 6*7>/*,=>;270 We anthe innovative and dynamic industry and memberslead have opportunity to play an active role in EuropaBioâ€™s main biotech sector councils (healthcare, ronmental products and services. '. 5.*- *7 2778?*=2?. *7- -B7*62, 27-><=;B *7- 6.6 ropaBioâ€™s main biotech as sector councils agri-food and industrial), well as in other (healthcare, expert com- bers have the opportunity to play an active role in Eu;89* 28E< 6*27 +28=.,1 <.,=8; ,8>7,25< 1.*5=1,*;. agri-foodworking and industrial), ascommunications well as in other expert com- +.;< 1*?. =1. 8998;=>72=B =8 95*B *7 *,=2?. ;85. 27 > mittees, groups, initiatives 5 EUROPEAN BIOTECHNOLOGY GUIDE 2015 EuropaBio also welcomes associate members such as *0;2 /88- *7- 27-><=;2*5 *< @.55 *< 27 8=1.; .A9.;= ,86 mittees, working groups, communications initiatives 5 EUROPEAN BIOTECHNOLOGY GUIDE 2015 and in developing EuropaBio policy agenda as well international commercial, financial, asset management and 62==..< @8;4270 0;8>9< ,866>72,*=287< 272=2*=2?.< %" ! $ ( % and in and developing EuropaBio policy agenda as well events networking opportunities. other service-providing companies, regional biotechnol*7- 27 -.?.589270 >;89* 28 9852,B *0.7-* *< @.55 events and networking opportunities. ogy development organisations and scientific institutes. .?.7=< *7- 7.=@8;4270 8998;=>72=2.< ] ] ] HEALTHCARE BIOTECH HEALTHCARE BIOTECH HEALTHCARE BIOTECH EUROPABIO â™Ľ â™Ľ â™Ľ TH TH $ European Biotech Week 2018: Exhibition in front of the EU Parliament showcasing contributions of biotechnology towards achieving the UN SDGs 2 \Ă&#x;3 2 \Ă&#x;3 2 \Ă&#x;3 We lead an innovative and dynamic industry and members have the opportunity to develop EuropaBioâ€™s policy agenda and to play an active role in our main biotech sector councils (healthcare, agri-food and industrial), expert committees, working groups, and communications initiatives including events and networking opportunities. 9 th european biotechnology guide 2019 64 | 65

European Biotechnology Guide 2019